COVID-19 Vaccine Uptake and Effectiveness by Time since Vaccination in the Western Cape Province, South Africa: An Observational Cohort Study during 2020–2022
Authors:
- Reshma KassanjeeRKReshma Kassanjee
- Mary-Ann DaviesMDMary-Ann Davies
- Alexa HeekesAHAlexa Heekes
- Hassan MahomedHMHassan Mahomed
- Anthony J. HawkridgeAHAnthony J. Hawkridge
- Erna MordenEMErna Morden
- Theuns JacobsTJTheuns Jacobs
- Cheryl CohenCCCheryl Cohen
- Harry MoultrieHMHarry Moultrie
- Richard J. LessellsRLRichard J. Lessells
- Nicolette Van Der WaltNWNicolette Van Der Walt
- Juanita O. ArendseJAJuanita O. Arendse
Open Access
Abstract
There are few data on the real-world effectiveness of COVID-19 vaccines and boosting in Africa, which experienced widespread SARS-CoV-2 infection before vaccine availability. We assessed the association between vaccination and severe COVID-19 in the Western Cape, South Africa, in an observational cohort study of >2 million adults during 2020–2022. We described SARS-CoV-2 testing, COVID-19 outcomes, and vaccine uptake over time. We used multivariable cox models to estimate the association of BNT162b2 and Ad26.COV2.S vaccination with COVID-19-related hospitalization and death, adjusting for demographic characteristics, underlying health conditions, socioeconomic status proxies, and healthcare utilization. We found that by the end of 2022, 41% of surviving adults had completed vaccination and 8% had received a booster dose. Recent vaccination was associated with notable reductions in severe COVID-19 during periods dominated by Delta, and Omicron BA.1/2 and BA.4/5 (sub)lineages. During the latest Omicron BA.4/5 wave, within 3 months of vaccination or boosting, BNT162b2 and Ad26.COV2.S were each 84% effective against death (95% CIs: 57–94 and 49–95, respectively). However, distinct reductions of effectiveness occurred at longer times post completing or boosting vaccination. Results highlight the importance of continued emphasis on COVID-19 vaccination and boosting for those at high risk of severe COVID-19, even in settings with widespread infection-induced immunity.Keywords
All Related Versions
Funding Information
- Western Cape Department of Health and Wellness for the Western Cape Provincial Health Data Centre (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
- US National Institutes for Health (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
- United States Agency for International Development (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
- Bill and Melinda Gates Foundation (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
- European Commission (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
- Grand Challenges ICODA pilot initiative delivered by Health Data Research UK and funded by the Bill & Melinda Gates and Minderoo Foundations (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
- Wellcome Trust (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
- Bill and Melinda Gates Foundation (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
This publication has 30 references indexed in Scilit:
- Evaluation of Waning of SARS-CoV-2 Vaccine–Induced ImmunityJAMA Network Open, 2023
- Service delivery challenges in HIV care during the first year of the COVID‐19 pandemic: results from a site assessment survey across the global IeDEA consortiumJournal of the International AIDS Society, 2022
- Efficacy and safety of COVID-19 vaccinesCochrane Database of Systematic Reviews, 2022
- Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control studyThe Lancet Infectious Diseases, 2022
- Vaccination plus previous infection: protection during the omicron wave in BrazilThe Lancet Infectious Diseases, 2022
- Waning effectiveness of COVID-19 vaccinesThe Lancet, 2022
- Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regressionThe Lancet, 2022
- Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in SwedenThe Lancet, 2022
- The National Advisory Group on Immunization (NAGI) of the Republic of South AfricaVaccine, 2010
- Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversyVaccine, 2009